Swimming in the Deep End of AI
In This Episode
Explore the cutting-edge intersection of AI and life sciences with the 'Life Sciences DNA' podcast, sponsored by Agilisium Labs. In this episode, host Dr. Amar Drawid engages with Brendan Frey, Founder and Chief Innovation Officer of Deep Genomics, to discuss how AI is revolutionizing therapeutic development. Discover how Deep Genomics leverages deep learning to analyze massive RNA biology datasets, paving the way for innovative therapies. Gain insights into how these advancements are unlocking the vast potential of RNA biology, enabling predictions of therapeutic outcomes with unprecedented accuracy.
- Explore the transformative role of AI in drug development and therapeutic innovation.
- Focus on Deep Genomics' pioneering use of deep learning in RNA biology analysis.
- Highlights how AI technologies, such as machine learning and generative AI, are enhancing drug discovery.
- Delve into the strategic decision to connect the genome with the molecular determinants of disease.
- Examine how these innovations are shaping the future of personalized medicine and healthcare.
- Provide an overview of AI's role in revolutionizing the life sciences industry.
Our Host
Dr. Amar Drawid
Dr. Amar Drawid, an industry veteran who has worked in data science leadership with top biopharmaceutical companies. He explores the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.
Our Speaker
Dr. Brendan Frey
Brendan Frey is the Founder and Chief Innovation Officer at Deep Genomics, a trailblazing company at the forefront of AI-driven therapeutic development. With a visionary approach, Brendan has been instrumental in merging the fields of AI and genomics to transform how therapies are discovered and developed. Over the past 15 years, he has co-authored more than 200 influential papers in machine learning and genome biology, with numerous publications in prestigious journals like Nature, Science, and Cell. Brendan’s groundbreaking work continues to shape the future of precision medicine, making him a pioneering figure in the biotech industry.
.avif)
.avif)
.avif)
.avif)
.avif)
